These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 33539535

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. FSTL3 deletion reveals roles for TGF-beta family ligands in glucose and fat homeostasis in adults.
    Mukherjee A, Sidis Y, Mahan A, Raher MJ, Xia Y, Rosen ED, Bloch KD, Thomas MK, Schneyer AL.
    Proc Natl Acad Sci U S A; 2007 Jan 23; 104(4):1348-53. PubMed ID: 17229845
    [Abstract] [Full Text] [Related]

  • 6. The structure of FSTL3.activin A complex. Differential binding of N-terminal domains influences follistatin-type antagonist specificity.
    Stamler R, Keutmann HT, Sidis Y, Kattamuri C, Schneyer A, Thompson TB.
    J Biol Chem; 2008 Nov 21; 283(47):32831-8. PubMed ID: 18768470
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Differential synthesis and action of TGFß superfamily ligands in mouse and rat islets.
    Brown ML, Kimura F, Bonomi LM, Ungerleider NA, Schneyer AL.
    Islets; 2011 Nov 21; 3(6):367-75. PubMed ID: 21964310
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Heparin and activin-binding determinants in follistatin and FSTL3.
    Sidis Y, Schneyer AL, Keutmann HT.
    Endocrinology; 2005 Jan 21; 146(1):130-6. PubMed ID: 15471966
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Growth differentiation factor 9 (GDF9) suppresses follistatin and follistatin-like 3 production in human granulosa-lutein cells.
    Shi FT, Cheung AP, Huang HF, Leung PC.
    PLoS One; 2011 Jan 21; 6(8):e22866. PubMed ID: 21829661
    [Abstract] [Full Text] [Related]

  • 13. Overexpression of follistatin-like 3 in gonads causes defects in gonadal development and function in transgenic mice.
    Xia Y, Sidis Y, Schneyer A.
    Mol Endocrinol; 2004 Apr 21; 18(4):979-94. PubMed ID: 14739256
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Differential actions of follistatin and follistatin-like 3.
    Schneyer A, Sidis Y, Xia Y, Saito S, del Re E, Lin HY, Keutmann H.
    Mol Cell Endocrinol; 2004 Oct 15; 225(1-2):25-8. PubMed ID: 15451564
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Activin A and follistatin-like 3 determine the susceptibility of heart to ischemic injury.
    Oshima Y, Ouchi N, Shimano M, Pimentel DR, Papanicolaou KN, Panse KD, Tsuchida K, Lara-Pezzi E, Lee SJ, Walsh K.
    Circulation; 2009 Oct 20; 120(16):1606-15. PubMed ID: 19805648
    [Abstract] [Full Text] [Related]

  • 18. Synexpression group analyses identify new functions of FSTL3, a TGFβ ligand inhibitor.
    Robertson RD, Mukherjee A.
    Biochem Biophys Res Commun; 2012 Oct 26; 427(3):568-73. PubMed ID: 23022195
    [Abstract] [Full Text] [Related]

  • 19. Follistatin-like 3 (FSTL3) mediated silencing of transforming growth factor β (TGFβ) signaling is essential for testicular aging and regulating testis size.
    Oldknow KJ, Seebacher J, Goswami T, Villen J, Pitsillides AA, O'Shaughnessy PJ, Gygi SP, Schneyer AL, Mukherjee A.
    Endocrinology; 2013 Mar 26; 154(3):1310-20. PubMed ID: 23407452
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.